Ranpirnase

DB04950InvestigationalProtein Based Therapies

Ranpirnase is a ribonuclease enzyme found in Rana pipiens oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. It is the first ribonuclease...

Mechanism: Ranpirnase controls tumour growth by degrading RNA within cancer cells, resulting in inhibition of protein synthesis and arresting mitosis in G(1)phase.
Curator reviewed
Primary indication: For the treatment of various forms of cancer.Curator reviewed

Resolves to

Compound

UNIIZE15FIT23ECAS196488-72-9

What you can answer from here — as of February 21, 2021

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which companies are running trials of Ranpirnase, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account